Home
About
Overview
Sharing Data
ORCID
Help
History (2)
A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC.
Roles of the N domain of the AAA+ Lon protease in substrate recognition, allosteric regulation and chaperone activity.
See All 2 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC.
A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC. JTO Clin Res Rep. 2022 Jan; 3(1):100262.
View in:
PubMed
authors with profiles
Everett E. Vokes